Technical Analysis for MPH - Medicure Inc.

Grade Last Price % Change Price Change
F 1.030 0.00% 0.000
MPH closed down 4.63 percent on Thursday, April 18, 2024, on 4.25 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Expansion Breakdown Bearish Swing Setup 0.00%
Reversal New Lows Setup Bearish Swing Setup 0.00%
Volume Surge Other 0.00%
BB Squeeze Ended Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Bollinger Band Squeeze Range Contraction -4.63%
Narrow Range Bar Range Contraction -4.63%
BB Squeeze Started Range Contraction -4.63%
Oversold Stochastic Weakness -4.63%
MACD Bullish Signal Line Cross Bullish -4.63%

   Recent Intraday Alerts

Alert Time
Fell Below Previous Day's Low 2 days ago
2x Volume Pace 2 days ago
Down 2% 2 days ago
Down 1% 2 days ago
1.5x Volume Pace 2 days ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Medicure Inc. Description

Medicure Inc. (Medicure) is a pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. The Company operates in the biopharmaceutical industry segment. The Company's primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc. and distributed in the United States and its territories through the Company's United States subsidiary, Medicure Pharma, Inc. AGGRASTAT, a glycoprotein IIb/IIIa inhibitor (GPI), is used for the treatment of acute coronary syndrome (ACS). The Company is also engaged in the development of TARDOXAL for neurological disorders, such as Tardive Dyskinesia (TD). The Company has completed Phase IIa stage of development for TARDOXAL. The Company is also developing Transdermal AGGRASTAT, a cure for acute cardiology. Transdermal AGGRASTAT is in preclinical-stage of development.


Sector: Healthcare
Industry: Biotechnology
Keywords: Chemistry Marketing Medicine Pharma Pharmaceutical Clinic Drug Skin Organ Systems Biopharmaceutical Disorders Pharmaceutical Industry Cardiology Neurological Disorders

Is MPH a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 1.8
52 Week Low 0.93
Average Volume 3,988
200-Day Moving Average 1.310
50-Day Moving Average 1.255
20-Day Moving Average 1.112
10-Day Moving Average 1.087
Average True Range 0.051
RSI (14) 39.39
ADX 14.03
+DI 33.352
-DI 52.866
Chandelier Exit (Long, 3 ATRs) 1.147
Chandelier Exit (Short, 3 ATRs) 1.183
Upper Bollinger Bands 1.214
Lower Bollinger Band 1.009
Percent B (%b) 0.1
BandWidth 18.390
MACD Line -0.058
MACD Signal Line -0.058
MACD Histogram 0.0008
Fundamentals Value
Market Cap 10.76 Million
Num Shares 10.5 Million
EPS -0.18
Price-to-Earnings (P/E) Ratio -5.85
Price-to-Sales 0.79
Price-to-Book 0.32
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.105
Resistance 3 (R3) 1.113 1.097 1.093
Resistance 2 (R2) 1.097 1.078 1.093 1.088
Resistance 1 (R1) 1.063 1.066 1.055 1.055 1.084
Pivot Point 1.047 1.047 1.043 1.043 1.047
Support 1 (S1) 1.013 1.028 1.005 1.005 0.976
Support 2 (S2) 0.997 1.016 0.993 0.972
Support 3 (S3) 0.963 0.997 0.968
Support 4 (S4) 0.955